Hormone replacement therapy in a risk-benefit perspective

Maturitas

Volumn 23, Issue 2, 1996, Pages 247-259

  Daly, E ^a   Vessey, M P ^a   Barlow, D ^a   Gray, A ^a   McPherson, K ^a   Roche, M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cost effectiveness analysis; Disease risk; Health care costs; Hormone Replacement Therapy; Menopause

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; CARDIOVASCULAR DISEASE; COMPUTER MODEL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; OSTEOPOROSIS; RISK BENEFIT ANALYSIS;

EID: 0029896006     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(95)00978-7     Document Type: Conference Paper

References (57)

1. Perrson I, Adami H-O, Bergkvist L et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J 1989; 298: 147-151.
2. Ross RK, Pike MC, Henderson BE, Mack TM, Lobo RA. Stroke prevention and oestrogen replacement therapy. Lancet 1989; 1: 505.
3. Bush TL, Miller VG. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell DR Jr, ed. Menopause: Physiology and Pharmacology. Chicago: Year Book Medical Publishers, 1987.
4. Jensen J. Effects of sex steroids on serum lipids and lipoproteins. Bailliere's Clin Obstet Gynaecol 1991; 5: 867-887.
5. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. J Am Med Assoc 1995; 273; 199-208.
6. Hunt K, Vessey M. The risks and benefits of hormone replacement therapy: an updated review. Curr Obstet Gynaecol 1991; 1: 21-27.
7. Hillard TC, Whitcroft S, Ellerington MC, Whitehead MI. The long-term risks and benefits of hormone replacement therapy. J Clin Pharm Ther 1991; 16 (4): 231-245.
8. Adami H-O. Long-term consequences of estrogen and estrogen-progestin replacement. Cancer Causes and Control 1992; 3: 83-90.
9. Jacobs HS, Loeffler FE. Postmenopausal hormone replacement therapy. Brit Med J 1992; 305: 1403-1408.
10. Barrett-Connor E. Risks and benefits of replacement estrogen. Annu Rev Med 1992; 43: 239-251.
11. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
12. Session DR, Kelly AC, Jewelewicz R. Current concepts in estrogen replacement therapy in the menopause. Fertil Steril 1993; 59: 277-284.
13. Weinstein MC, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Survey 1983; 38: 445-455.
14. Roche M, Vessey MP. Hormone replacement in the community: risks, benefits and costs. In: Drife JO, Studd JWW, eds. HRT and Osteoporosis. London:Springer-Verlag, 1990.
15. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. Hormone replacement therapy: an analysis of benefits, risks and costs. Br Med Bull 1992; 48: 368-400.
16. Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 1992; 156: 312-316.
17. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Eng J Med 1977; 296: 716-721.
18. Spector TD. Use of oestrogen replacement therapy in high risk groups in the United Kingdom. Br Med J 1989; 299: 1434-1435.
19. Barlow DH, Brockie JA, Rees CMP. Study of general practice consultations and menopausal problems. Br Med J 1991; 302: 274-276.
20. Office of Population Censuses and Surveys. Mortality Statistics: cause 1990. London: HMSO, 1992.
21. Department of Health and Social Security and Office of Population Censuses and Surveys. Hospital In-patient Enquiry 1985. London: HMSO, 1987.
22. Boyce WJ, Vessey MP. Rising incidence of fracture of the proximal femur. Lancet 1985; 1: 150-151.
23. Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population. J Epidemiol Community Health 1990; 44: 241-245.
24. Melton LJ, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertobral fractures in women. Am J Epidemiol 1989; 129: 1000-1011.
25. British National Formulary Number 25 (March 1993). London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 1993.
26. Social Services Select Committee, 8th report. London: HMSO, 1989.
27. Department of Health and Social Security and Office of Population Censuses and Surveys. Morbidity Statistics from General Practice, Third National Study 1981-1982. London: HMSO, 1986.
28. Cooper C, Melton LJ. Vertebral fractures: How large is the silent epidemic? Br Med J 1992; 304: 793-794.
29. Health and Personal Social Services Statistics. London: HMSO, 1989.
30. Goddard M, Hutton J. The costs of radiotherapy in cancer treatment. Discussion Paper No. 48. University of York, Centre for Health Economics, 1988.
31. Cubbon J. The principle of QALY maximisation as the basis for allocating health care resources. J Med Ethics 1991; 17: 181-184.
32. Harris J. Unprincipled QALYs: a response to Cubbon. J Med Ethics 1991; 17: 185-188.
33. Wade DT. The "Q" in QALYs. BMJ 1991; 303: 1136-1137 (letter).
34. Editorial. Quality of Life. Lancet 1991; 338: 350-351.
35. Smith A. Qualms about QALYs. Lancet 1987; 1134-1136.
36. McTurk L. A methodological quibble about QALYs. Br Med J 1991; 302: 1601 (letter).
37. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. Br Med J 1993; 307: 836-840.
38. Hunt K. Perceived value of treatment among a group of long-term users of hormone replacement therapy. J R Coll Gen Pract 1988; 38: 398-401.
39. McKinlay SM, Jefferys M. The menopausal syndrome. Br J Prev Soc Med 1974; 28: 108-115.
40. Hillner BE, Hollenberg JP, Pauker SG. Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Am J Med 1986; 80: 1115-1127.
41. Ross RK, Paganini-Hill A, Mack TM, Henderson BE. Estrogen use and cardiovascular disease. In: Mishell DR, Jr, ed. Menopause: physiology and pharmacology. Chicago: Year Book Med Publ 1987; 209-223.
42. Sitruk-Ware R, de Palacios PI. Oestrogen replacement therapy and cardiovascular disease in post-menopausal women. A review. Maturitas 1989; 11: 259-274.
43. Miller AB. Risk/benefit considerations of antiestrogen/estrogen therapy in healthy postmenopausal women. Prev Med 1991; 20: 79-85.
44. Falkeborn M, Persson I, Adami H-O, Bergstrom R, Eaker E, Lithell H, Mohsen R, Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821-828.
45. Falkeborn M, Persson I, Terent A, Adami H-O, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke: Follow-up of a population-based cohort in Sweden. Arch Intern Med 1993; 153: 1201-1209.
46. Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992; 48 (2): 276-308.
47. Goldman L, Tosteson ANA. Uncertainty about postmenopausal estrogen: Time for action, not debate. N Engl J Med 1991; 325: 800-802.
48. Vandenbrouke JP. Postmenopausal oestrogen and cardio-protection. Lancet 1991; 337: 833-834.
49. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141-1146.
50. Randall S. Problems encountered by long-term hormone replacement therapy users. Br J Fam Planning 1990; 16: 101-105.
51. Wilkes H, Meade TW. Hormone replacement therapy in general practice. Br Med J 1991; 303: 416-417.
52. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health 1989; 43: 173-178.
53. Adam S, Williams V, Vessey MP. Cardiovascular disease and hormone replacement treatment; a pilot case-control study. Br Med J 1981; 282: 1277-1278.
54. Wilkes HC, Meade TW. Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. Br Med J 1991; 302: 1317-1320.
55. Williams A. Screening for risk of CHD: Is it a wise use of resources? In: Oliver M, Ashley-Miller M, Wood D, eds. Screening for risk of coronary heart disease. Chichester: Wiley, 1987.
56. Williams A. Economics of coronary artery bypass grafting. Br Med J 1985; 291: 326-329.
57. Coulter A, McPherson K, Vessey MP. Do British women undergo too many or too few hysterectomies? Soc Sci Med 1988; 27: 987-994.